BeiGene, Ltd. (HKG:6160)
161.70
-3.20 (-1.94%)
Apr 3, 2025, 10:45 AM HKT
BeiGene Revenue
In the year 2024, BeiGene had annual revenue of $3.81B USD with 54.96% growth. BeiGene had revenue of $1.19B in the quarter ending December 31, 2024, with 84.84% growth.
Revenue
$3.81B
Revenue Growth
+54.96%
P/S Ratio
n/a
Revenue / Employee
$346.39K
Employees
11,000
Market Cap
229.95B HKD
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 3.81B | 1.35B | 54.96% |
Dec 31, 2023 | 2.46B | 1.04B | 73.65% |
Dec 31, 2022 | 1.42B | 239.64M | 20.37% |
Dec 31, 2021 | 1.18B | 867.41M | 280.83% |
Dec 31, 2020 | 308.87M | -119.34M | -27.87% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Hansoh Pharmaceutical Group Company | 13.05B |
JD Health International | 61.89B |
WuXi Biologics | 19.87B |
Innovent Biologics | 10.03B |
Alibaba Health Information Technology | 31.39B |
Akeso | 2.26B |
Sichuan Kelun-Biotech Biopharmaceutical | 2.06B |
Sino Biopharmaceutical | 30.72B |
BeiGene News
- 2 days ago - BeiGene Receives Positive CHMP Opinion for TEVIMBRA® as a First-Line Treatment for Extensive-Stage Small Cell Lung Cancer - Business Wire
- 4 weeks ago - China-Based Biotech BeiGene Scores FDA Approval For Tevimbra/Chemo Combo For Untreated Patients With Esophageal Cancer - Benzinga
- 4 weeks ago - BeiGene wins FDA nod for Tevimbra in first-line esophageal cancer - Seeking Alpha
- 4 weeks ago - BeiGene: Q4 Results Impress With Positive Earnings Expected In 2025 - Seeking Alpha
- 4 weeks ago - Q4 2024 Beigene Ltd Earnings Presentation Transcript - GuruFocus
- 4 weeks ago - BeiGene, Ltd. (ONC) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - BeiGene Ltd (ONC) Q4 2024 Earnings: EPS of -$0.11 Beats Estimates, Revenue Surges to $1.1 Billion - GuruFocus
- 4 weeks ago - BeiGene reports Q4 results - Seeking Alpha